Background: Acute small bowel obstruction caused by bezoars is rare and, therefore, this problem is not well known by a community of doctors worldwide. Hence, there is high frequency of diagnostic and tactical errors and often probability of late operations. The aim of this research is to study possible reasons for the bezoar formation, clinical course and treatment of intestinal obstruction caused by bezoars. Methods: The present report is based on a retrospective analysis of medical records of 15 patients suffered from this form of intestinal obstruction, who were treated at the Moscow Clinical Hospital № 71 over the last 20 years. The mean age of the patients was 67.2 ± 3.4. The diagnosis was established on the basis of complaints of patients, anamnesis, results of physical examination and x-ray. 8 patients had previously undergone a gastric resection for ulcer, 1 had undergone selective proximal vagotomy and 1 had undergone stem vagotomy with pyloroplasty. Results: Acute small bowel obstruction caused by bezoar occurred in all 10 patients, who were operated earlier. It is associated with the fact that the above mentioned operations violate secretory and motor functions of the stomach causing the movement of poorly digested pieces of food to the small intestine and bezoar formation. Formation of bezoar is promoted by such factors as poor dental health, which does not provide proper chewing of plant products (persimmons, grapes and grapefruit) and animal products (meat), and quick swallowing, too. In the majority of patients, the course of small bowel obstruction was intermittent. All the patients were operated with diagnosis of acute intestinal obstruction. The assumption about the true nature of obstruction appeared in only 3 cases. In 10 cases bezoars were located in the ileum, and in 5 -in the jejunum. Bezoars were removed with enterotomy in 13 patients, in 2 -with fragmentation and transposition in the cecum. All operated patients have recovered. Conclusions: Timely diagnosis of small bowel obstruction caused by bezoar is possible by a thorough analysis of anamnestic data (information about the previous operations on the stomach, food, dental health, and character of food chewing) as well as the particular features of its clinical course, which should be intermittent. Bezoar shall be removed from enterotomy made below the obstruction, where the bowel wall microcirculatory disorders are minimal. Background: Strict adherence to the established standards 1 is expected in the communication of abnormal laboratory results between the laboratory and the ward. Upon receiving abnormal laboratory results, the laboratory personnel will phone and inform the ward about the results. The receiver will take the necessary actions and then transfer the abnormal results into the patient's charts. In a three-week audit conducted, we compared the compliance of all wards in SVUH in acting upon and transferring the abnormal laboratory results into the charts against the standards set by Joint Commission International (JCI), whereby 100% compliance towards the process is expected. Methods: Retrospective, random data collection of 100 abnormal laboratory results (50-biochemistry and 50-haematology) were compared to the details found in the corresponding patients charts using a data collection form consisting of three questions. Results: Out of 100 cases, 39% of abnormal laboratory results were not written down, the team was not told and there was no action taken (all YES). In 32% of cases, the results were written down, the team was told and action was taken (all NO). In 27% of cases, the results were not written down and there was no indication that team was told but action was taken. In 2% of cases, the results were written down and team was told but action was not taken. Out of 13 wards, 2 reported high rates of compliance (3/3 and 6/8 cases with all YES) and 2 exhibited high rates of non-compliance (6/13 and 6/7 cases with all NO). One ward quoted a 'different nursing care plan' for their non-compliance. Conclusions: Our study discovered a worryingly high non-compliance rate among medical ward staff towards the process of transferring the abnormal laboratory results into patients' charts, while full compliance rate is low at 32%. There are inconsistencies between the different nursing care plans and the delay in the timely follow-up of patients' abnormal laboratory results raises a safety concern. We propose the use of detachable stickers that could be peeled off and pasted into patients' charts to increase compliance. Background: B-cell Chronic Lymphocytic Leukemia (CLL) is the most common leukemia diagnosed in adults in the western world. Multiple Myeloma (MM), a plasma cell neoplasm based in bone-marrow, comprises about 1% of all malignant tumours. These are two incurable disorders with treatments that focus on controlling the disease and symptoms rather than eradicating it. Synthetic analogues of Retinoic Acid (RA) are currently used extensively for the treatment of skin disorders such as acne vulgaris and psoriasis, as well certain forms of cancer namely Acute Promyelocytic Leukemia. Preclinical studies have also garnered support for their chemopreventive potential in many more cancers, especially haematological malignancies. The purpose of this study was to illustrate the roles of Fenretinide (4HPR) and Acitretin in CLL and MM and establish whether the two retinoic acid derivatives may prove to be prospective treatments for these malignancies. Fenretinide (4HPR) is a drug studied in a variety of cancers and has shown to induce apoptosis through increased levels of Reactive Oxygen Species (ROS) and activation of caspase-8, 9 and 3. Acitretin is currently used to treat psoriasis but little is known about its effect on cancer. Therefore, its mechanism of action is unknown. Results: For the purpose of this study, 5 MM cell lines (RPMI-8226, NCI-H929, MM1.s, KMS-BM-12, U-266) and primary cells isolated from whole blood of CLL patients were used. 4HPR significantly decreased cell viability in 4 out of 5 MM cell lines tested at 5, 10, 20μM, whereas Acitretin only had an effect at concentrations higher than 50uM in 2 MM cell lines. CLL cells were highly sensitive to 4HPR at all concentrations used, but were only sensitive to Acitretin up until 10μM. 4HPR and Acitretin also significantly decreased NCI-H929 and CLL cells migration capabilities. Additionally, western blot analysis on RPMI-8226 cells showed that 4HPR and Acitretin negatively affected the expression of the cell cycle markers cyclin D2 and phospho-Rb, the anti-apoptosis marker Mcl-1, and increased cleavage and therefore activation of the pro-apoptotic marker PARP. This suggests that the two inhibitors could affect both cell proliferation and apoptosis. Conclusions: Having conveyed promising cytotoxic and chemoattractant properties with both CLL and MM cells, 4HPR and Acitretin have proven to be promising therapeutic candidates for MM and CLL treatment. Introduction: It is widely believed that platelet responsiveness can be used as a marker for assessing thrombotic risk in patients. Therefore, there have been many attempts to develop suitable assays for quantifying platelet responses in clinical samples 1. Platelet aggregometry is widely used, but is limited in its ability to assess platelet hyper-responsiveness. In order to develop a better assay of thrombotic risk, we use a novel assay to evaluate platelet secretion of adenosine triphosphate & diphosphate (ATP/ADP) in response to various agonists. This assay measures both the maximal amount of adenine nucleotides released by a range of platelet activators and the potency of each activator. Methods: To determine the reproducibility of this assay, we assessed 4 healthy female subjects on 3 separate occasions. 10mls of blood was drawn from subjects who had abstained from medication for the previous 12 days. Platelet ATP/ADP secretion was assessed in a 96 well assays as previously described 2. Briefly, platelet secretion is assessed in response to increasing doses of platelet agonists (Thrombin receptor activating peptide: TRAP 0.1-32µM; Collagen related peptide: CRP 0.05-100µg/ml). Released ATP/ADP is measured using firefly luciferase (Chronolume Corp). Data are expressed as nmoles ATP/ADP secreted per 10 6 platelets. Doseresponse curves are constructed and analysed using GraphPad Prism 5.0. Results: The maximal amount of ATP/ADP released is similar for both agonists tested (1.94±0.25 and 2.12±0.28 nmoles per 10 6 platelets in response to TRAP and CRP, respectively). However, the potency of responses, measured as EC 50 values, differed for the two agonists. For TRAP, the EC 50 values were equivalent in all 4 donors (mean EC 50 value is 4.84 ± 0.30µM; range 4.38-5.57µM). in response to CRP, the potency of the responses were nearly similar for all the donors (EC 50 range from 0.37µg/ml to 1.08µg/ml). Nonetheless, there is a high degree of concordance within all samples from any one donor.
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Background: B-cell Chronic Lymphocytic Leukemia (CLL) is the most common leukemia diagnosed in adults in the western world. Multiple Myeloma (MM), a plasma cell neoplasm based in bone-marrow, comprises about 1% of all malignant tumours. These are two incurable disorders with treatments that focus on controlling the disease and symptoms rather than eradicating it. Synthetic analogues of Retinoic Acid (RA) are currently used extensively for the treatment of skin disorders such as acne vulgaris and psoriasis, as well certain forms of cancer namely Acute Promyelocytic Leukemia. Preclinical studies have also garnered support for their chemopreventive potential in many more cancers, especially haematological malignancies. The purpose of this study was to illustrate the roles of Fenretinide (4HPR) and Acitretin in CLL and MM and establish whether the two retinoic acid derivatives may prove to be prospective treatments for these malignancies. Fenretinide (4HPR) is a drug studied in a variety of cancers and has shown to induce apoptosis through increased levels of Reactive Oxygen Species (ROS) and activation of caspase-8, 9 and 3. Acitretin is currently used to treat psoriasis but little is known about its effect on cancer. Therefore, its mechanism of action is unknown. Results: For the purpose of this study, 5 MM cell lines (RPMI-8226, NCI-H929, MM1.s, KMS-BM-12, U-266) and primary cells isolated from whole blood of CLL patients were used. 4HPR significantly decreased cell viability in 4 out of 5 MM cell lines tested at 5, 10, 20μM, whereas Acitretin only had an effect at concentrations higher than 50uM in 2 MM cell lines. CLL cells were highly sensitive to 4HPR at all concentrations used, but were only sensitive to Acitretin up until 10μM. 4HPR and Acitretin also significantly decreased NCI-H929 and CLL cells migration capabilities. Additionally, western blot analysis on RPMI-8226 cells showed that 4HPR and Acitretin negatively affected the expression of the cell cycle markers cyclin D2 and phospho-Rb, the anti-apoptosis marker Mcl-1, and increased cleavage and therefore activation of the pro-apoptotic marker PARP. This suggests that the two inhibitors could affect both cell proliferation and apoptosis. Conclusions: Having conveyed promising cytotoxic and chemoattractant properties with both CLL and MM cells, 4HPR and Acitretin have proven to be promising therapeutic candidates for MM and CLL treatment. Introduction: It is widely believed that platelet responsiveness can be used as a marker for assessing thrombotic risk in patients. Therefore, there have been many attempts to develop suitable assays for quantifying platelet responses in clinical samples 1. Platelet aggregometry is widely used, but is limited in its ability to assess platelet hyper-responsiveness. In order to develop a better assay of thrombotic risk, we use a novel assay to evaluate platelet secretion of adenosine triphosphate & diphosphate (ATP/ADP) in response to various agonists. This assay measures both the maximal amount of adenine nucleotides released by a range of platelet activators and the potency of each activator. Methods: To determine the reproducibility of this assay, we assessed 4 healthy female subjects on 3 separate occasions. 10mls of blood was drawn from subjects who had abstained from medication for the previous 12 days. Platelet ATP/ADP secretion was assessed in a 96 well assays as previously described 2. Briefly, platelet secretion is assessed in response to increasing doses of platelet agonists (Thrombin receptor activating peptide: TRAP 0.1-32µM; Collagen related peptide: CRP 0.05-100µg/ml). Released ATP/ADP is measured using firefly luciferase (Chronolume Corp). Data are expressed as nmoles ATP/ADP secreted per 10 6 platelets. Doseresponse curves are constructed and analysed using GraphPad Prism 5.0. Results: The maximal amount of ATP/ADP released is similar for both agonists tested (1.94±0.25 and 2.12±0.28 nmoles per 10 6 platelets in response to TRAP and CRP, respectively). However, the potency of responses, measured as EC 50 values, differed for the two agonists. For TRAP, the EC 50 values were equivalent in all 4 donors (mean EC 50 value is 4.84 ± 0.30µM; range 4.38-5.57µM). in response to CRP, the potency of the responses were nearly similar for all the donors (EC 50 range from 0.37µg/ml to 1.08µg/ml). Nonetheless, there is a high degree of concordance within all samples from any one donor. Conclusion: Our data demonstrate that individual donors display unique response-parameters which may be used to assess thrombotic risk. In addition, we can conclude that the dose of agonist that causes a halfmaximal response is a reliable index of platelet responsiveness. Results: Statistically significant difference (p < 0.01) between the two groups, in flexion and abduction movements, was reported. Within group analysis, from preoperative period to 12th month, showed absence of statistically significant difference in the TG, while at same time proved statistically significant difference (p < 0.05) in the CG regarding flexion, abduction and internal rotation movements. This evidence that TG regained normal function at 1 year after rehabilitation treatment while CG was unable to do so for flexion, abduction and internal rotation movements. Statistically significant differences (p < 0.001) were observed in terms of pain perception starting from the first month. Results analysis showed effectiveness of rehabilitation treatment in improving patient's quality of life.
Conclusions: Postoperative early PRP in breast cancer patients surgically treated with axillary dissection improves significantly the glenohumeral joint mobility, permitting the patients to regain normal shoulder function, reduces pain and widely improves QoL. Authors recognise it as a very intensive rehabilitation programme. They still believe, however, that early rehabilitation should be part of the standard treatment in patient with breast cancer following axillary dissection having a key role in patient's physical and psycho-social recovery. 3 and IKCa1 channels enable the specific modulation of different lymphocyte subsets. The ratio of the above channels is dissimilar in different types of lymphocytes. The inhibition of these channels leads to reduced activation of lymphocytes, and, therefore, to a decrease of the autoimmune reaction. In our investigations we aimed to observe the differences in lymphocyte activation upon the inhibition of the above channels in the Th1, Th2, CD4 and CD8 subsets in MS compared to healthy individuals. Furthermore, we aimed to assess whether inhibition of lymphocyte potassium channels may be a possible target for the future therapy of MS. Methods: We used flow cytometry for our investigations. We analyzed samples of 10 healthy individuals and 10 newly diagnosed MS patients not receiving immunomodulatory therapy. First, we separated lymphocytes and stained the Th1, Th2, CD4 and CD8 subsets with cell surface markers. Then, cells were loaded with calcium-sensitive fluorescent dyes and were treated with the blockers of the above-mentioned channels. We activated cells with phytohemagglutinine immediately before the flow cytometry recording. Finally, data were evaluated by a software developed in our laboratory. Results: In MS, the reactivity of lymphocytes is increased compared to healthy controls. In MS there was no difference revealed between the investigated subsets upon blocking the IKCa1 channels. The inhibition of Kv1.3 channels in MS decreased the activation of CD8 cells to a higher extent than that of CD4 cells, but such a difference was not detectable between Th1 and Th2 cells. Conclusions: Our findings suggest that the activation of lymphocytes can be decreased in MS by blocking the investigated channels. Although limited selectivity can be reached in MS. Accordingly, further investigation is needed to assess how the inhibition of lymphocyte potassium channels modulates the whole immune response in MS.
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Breast clinic referrals -should mastalgia be managed in primary care? Jamal Alamiri * , AJ Lowery, S Rajendran, AD Hill Beaumont Hospital, Dublin, Ireland E-mail: jamalalamiri@rcsi.ie BMC Proceedings 2013, 7(Suppl 1):O7 Background: Following centralisation of breast cancer services in Ireland, the number of patients attending symptomatic breast units (SBU) has increased significantly. A considerable proportion of patients referred to SBU present with non-suspicious symptoms and fall into a "low-risk" category for breast cancer. It has been proposed that consideration be given to a GPdelivered service for these patients. Aim: To evaluate SBU attendances and correlate with diagnosis to identify a cohort of patients who may be suitable for management in the primary care setting. Methods: Data was collected from a prospectively maintained database on patients attending SBU at Beaumont Hospital from January 2011 -May 2012. Reasons for attendance, outcome of triple-assessment and incidence of malignancy were analysed.
Results: Findings: 6,019 patients underwent triple-assessment at the SBU in this time-period. 1,959 patients were referred with mastalgia, of whom 1,022 (52.2%) reported mastalgia as their only symptom. The incidence of breast cancer in patients presenting with mastalgia alone was 0.8%; all patients diagnosed with breast cancer in this cohort were over 40 years of age. There was no breast cancer diagnosed in patients under 35yrs referred to SBU with mastalgia, and the majority of these patients had a normal breast examination (S2) (82.57%).
Conclusion:
The incidence of breast cancer in patients referred to SBU with mastalgia as an isolated symptom is extremely low. Patients under35yrs, with mastalgia as an isolated symptom do not require breast imaging and have a sufficiently low risk of breast cancer that they may be suitable for management in the primary-care setting.
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Targeting mutant BRAF in colorectal cancer David Carroll * , R Carson, S Van Schaeybroeck, PG Johnston Queens University, Belfast, United Kingdom E-mail: davidcarroll06@qub.ac.uk BMC Proceedings 2013, 7(Suppl 1):O8 Background: Mutations in BRAF V600E oncogene (BRAFMT) occurs in 8-15% of colorectal cancer (CRC) patients1. This mutation constitutively activates MAPK signalling, resulting in a proliferative and survival advantage for the tumour cells and oncogenic BRAF status has been linked with poor prognosis2. Despite introduction of the BRAFMT specific inhibitor Vemurafenib in metastatic melanoma3, there is no effective treatment strategy for BRAFMT CRC patients. This study aimed to assess the effectiveness of Ganetespib (HSP90 inhibitor), the multi-kinase inhibitor (CRAF/VEGFR/PDGFR) Sorafenib and the BRAFMT inhibitor Vemurafenib in BRAFMT CRC cell line models. Methods: BRAF MT RKO F6-8 (MT/WT) and isogenic wild-type T29 (null/WT) cell lines were used. MTT assays were used to determine IC50 values. Protein expression was determined by Western Blotting. Levels of apoptotic cells were assessed by flow cytometry. Results: The RKO BRAFMT cell line was equally sensitive to Sorafenib and Ganetespib compared to the isogenic BRAFWT clone (IC50 1.4µM vs. 0.9 µM and 0.86 nM vs. 0.79nM respectively). Vemurafenib treatment resulted in a strong decrease in MAPK signalling and showed greater specificity towards BRAFMT cells (IC50 of 2.4µM vs. 3.3 µM) than BRAFWT cells in cell viability assay. Western blotting showed that neither Sorafenib nor Ganetespib had an observable effect in targeting mutant BRAF. Sorafenib did have some effect at targeting downstream MAPK signalling however Ganetespib had no observable effect on targeting the MAPK pathway in BRAF mutant cell lines. Vemurafenib targeted BRAF and downstream MEK activation in both mutant-type cell lines but not in the wild-type cell lines. We also found that treatment with Vemurafenib induced activation of the STAT3 survival pathway, highlighting a resistance pathway which may be activated in response to treatment in BRAFMT cell lines. Conclusions: Despite the number of compounds which can target BRAFMT cell lines through inhibition of mutant BRAF directly or indirectly through inhibition of other pathways, our studies have shown that Vemurafenib is the most effective treatment strategy in the cell line model tested. Effects of Ganetespib or Sorafenib treatment did not display specificity towards BRAFMT cells alone nor an effect on mutant BRAF. Vemurafenib has shown selectivity towards BRAFMT cells in which a reduction in MAPK signaling is achieved along with induction of apoptosis. Evidence of the emergence of a potential resistance mechanism via STAT3 following Vemurafenib treatment was also found giving insight into the kinome reprogramming event which takes place following treatment. 3%-3 .8%) and sexual pathway (*35.4% to 42.3%) of transmission whereas a decrease in parenteral pathway (*62.3% to 53.9%). *p<0.001 (e) Number of infected males increased from 56.3% to 60.1% (p<0.001) and infected females decreased from 43.7% to 39.9% (p<0.001). Conclusions: Insufficient surveillance system can result in high number of incidence rates in NNR, VFR and RF and pronounced increasing trend of prevalence rate in VFR and RF from 2006-2010. The disadvantages in surveillance system can also be related to increases in placental and sexual modes of transmission and infected male sex distribution.
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Oxidative and nitrative stress as a pathogenic factor in multiple sclerosis Štefan Lukáč Background: Multiple sclerosis (MS) is an autoimmune disease of central nervous system, which unknown etiology, but recent studies suggest important role of oxidative stress in its pathogenesis. The aim of our study was to analyze various markers of oxidative and nitrative damage, their mutual correlations and correlations with the state of the blood-brain barrier (BBB) in multiple sclerosis patients. We also monitored the level of uric acid, an antioxidant. Methods: 58 samples of blood plasma from patients with suspect MS and 43 ones from healthy people were analyzed. The function of BBB in tested group was evaluated using the QA index that indicated its damage in 7 males and 3 females. We estimated total antioxidant status, level of lipoperoxides, markers of protein deterioration by oxidative stress-protein carbonyls and by nitrative stress-3-nitrotyrosine. Also uric acid concentration in males and females was detected. Student T-test and Pearson correlation coefficient were used for evaluating of statistical significance. Results are presented as average value ± SD. Statistical significance is calculated to the control group. Results: Summary of the results is in Table 1 . Our study confirms earlier findings of decreased total antioxidative status in patients with MS and also increased lipoperoxidation, which positively correlated with the state of BBB. This finding induces role of lipid peroxidation by deterioration in the quality of blood-brain barrier. Elevated levels of protein carbonyls confirmed oxidative damage of plasma proteins, which are also attacked by nitrative stress, as evidenced by increased level of 3-nitrotyrosine and a positive correlation between 3-nitrotyrosine and protein carbonyls. Uric acid, which level was physiological, negatively correlated with protein carbonyls, what suggests its role in protection of proteins against oxidative stress, confirmed by the positive correlation with TAS. Conclusions: Based on these results, we can conclude that oxidative and nitrative stress are important factors in the pathogenesis of MS with effect on a wide range of substances. Therefore, it is necessary to pay attention to their reduction in the therapeutic process. Background: Not long ago, osteoporosis was considered a normal condition specific to old age; presently, osteoporosis is an affection characterized through the reduction of the mineral bone density associated with the impairment of the trabecular bone structure and implicitly with the increase of the bone fragility. Compliance and adherence to osteoporosis management are of high priority, having a significant effect on the cost effectiveness of therapy 1. Methods: The evaluation of the phosphocalcium metabolism for the female patients with osteoporosis, before and after 1 year since the administration of antiresorptive drugs, was realized through osteodensitometry (BMD), that was the most conclusive paraclinical exam used in the diagnosis of osteoporosis, the evaluation of the clinical factors and the analysis of the bone turnover through the determination of the biochemical turn-over markers (BTM-bone formation and resorption, pre and post-therapy). Besides the specific analysis of these pathology was made blood analysis. Results: After 1 year since the administration of antiresorptive drugs wasn't noticed important modifications at the BMD and biochemical markers, could contribute to the creation of a pathogenic profile of the patient that led to a therapeutic decision as correct as possible. BTM changes can also be used for understanding the mechanism of action of drugs in development and identifying the correct dose 2,. Instead, at 2% of female patients could be noticed small decreases of the serum concentrations of calcium, as well as 
Conclusions:
The pharmacological therapy must be extended under periodical medical control in order to maximize the benefits and to avoid side effects since, depending on the results of the exams, it could be necessary to vary the doses or the type of used drug. The study of the hard support tissues is rendered difficult by the fact that the bone is one of the most unstable tissues from the organism.
Introduction: A 'gender gap' exists in Cystic Fibrosis (CF). Females acquire earlier microbial infections; have worse lung function and poorer survival rates [1] . The sex-hormone estrogen (estradiol, E2) has recently been highlighted as a key molecule responsible for the CF gender dichotomy [2] . Pseudomonas aeruginosa which colonises the CF lung and dominates at end stage disease undergoes mucoid conversion in response to E2 [2, 3] . The aim of this project was to study other roles of E2 in host and pathogen responses by investigating its effects on the growth rate of Ps. aeruginosa and the expression of catalase and superoxide dismutase (SOD) in CF bronchial epithelial cells. Methods: Growth rate of Ps. aeruginosa (PA01) in the presence or absence of E2 was measured by recording optical density (OD 600nm ) at different time points and by calculating cfu/ml. Measurements of catalase and SOD gene expression in E2-treated CFBE410-airway epithelial cells were carried out using real time qRT-PCR. Results were analysed using Graphpad PRISM 5.0. Results: E2 had no effect on the growth of Ps. aeruginosa when compared to control. The expression of catalase mRNA in CFBE410-cells in response to E2 was not altered however, there was two-fold increase in SOD gene expression in response to 10 nM E2, 24hr (p= 0.0057). Conclusion: Estradiol has no effect on the growth of Ps. aeruginosa in vitro.
In CF bronchial epithelial cells although catalase gene expression remains unchanged, E2 increases SOD expression, potentially increasing hydrogen peroxide levels and contributing to Ps. aeruginosa mucoid conversion.
